Video

Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL

Author(s):

James K. McCloskey II, MD

In Partnership With:

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia.

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia (ALL).

CD19 is an ideal target in B-cell ALL, says McCloskey, as it is expressed on the surface of the cells of these patients.

The antibody-drug conjugate loncastuximab tesirine (ADCT-402), which is designed to target CD19, is currently being evaluated in patients with relapsed or refractory B-cell ALL.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center
November 21st 2024

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

Andre H. Goy, MD, vice president, physician in chief, Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma, academic chairman, Oncology, Hackensack Meridian School of Medicine; professor, medicine, Georgetown University
May 6th 2024

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL